Navigation Links
Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
Date:5/31/2008

Positive Interim Safety and Efficacy Data Reported

Trial Enrollment Advancing Ahead of Schedule

SOUTH SAN FRANCISCO, Calif., May 31 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today presented an update of interim data from the company's ongoing Phase 2 clinical trial of its lead product candidate, voreloxin (formerly SNS-595), in platinum-resistant ovarian cancer patients at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

"Voreloxin is a promising anti-cancer agent demonstrating encouraging signs of single-agent clinical activity in ovarian cancer patients who have failed prior rounds of treatment," said William McGuire, M.D., Medical Director of the Harry and Jeanette Weinberg Cancer Institute at Franklin Square and principal investigator for the Phase 2 clinical trial. "Importantly, treatment with voreloxin has resulted in disease control among approximately half of patients treated and the drug has been very well tolerated. Taken together, these data support a potentially broad therapeutic window for this product candidate and I look forward to seeing the outcomes of treatment with voreloxin at the higher dose levels for patients now enrolling in this study."

To date, voreloxin administered as a single agent at a dose of 48 mg/m(2) once every 21 days has demonstrated clinical activity in platinum-resistant ovarian cancer patients. Thus far, of 62 women evaluable for best response at that dose, one patient had a complete response, five patients had partial responses (one unconfirmed) and forty-five patients achieved stable disease. Forty-eight percent of these 62 patients achieved disease control, defined as stable disea
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
2. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
3. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
4. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
6. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
7. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
8. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
9. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
10. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
11. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Patient engagement has become ... organizations are turning to an assortment of marketing ... part of this evolving approach to patient engagement, ... and engage patients throughout their experiences with a ... By mapping the patient journey and employing a ...
(Date:7/11/2014)... , July 11, 2014 Research ... "Global Hypodermic Needles Market 2014-2018" report to their ... A hypodermic needle is a hollow needle commonly ... body or or to extract fluids from it. A ... or to inject substances that cannot be ingested. Hypodermic ...
(Date:7/11/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) has ... Testing Market - Forecasts to 2019: Expected to ... is expected to be valued at USD 4,943.0 ... http://photos.prnewswire.com/prnh/20130307/600769 The ... according to immunoprotein types which include immunoglobulins, complement ...
Breaking Medicine Technology:New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... and ABBOTT PARK, Ill., June 24, 2011 New ... The New England Journal of Medicine show ... and type 2 diabetes receiving bardoxolone methyl for 52 ... the treatment period, as measured by estimated glomerular filtration ...
... 24, 2011 , Comprehensive , F ... ow , A vailable in Canada, U.K. ... world-leading provider of scientific, technical and,medical information products and services, ... of the United States, enabling,institutions to identify international funding opportunities. ...
Cached Medicine Technology:New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 2New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 3New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 4Elsevier's SciVal Funding Expands Globally 2Elsevier's SciVal Funding Expands Globally 3
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, 2014 (HealthDay ... thought to be cured by immediate and aggressive drug treatment ... AIDS-causing virus in her bloodstream, disappointed federal officials announced Thursday ... remained virus-free even though she stopped taking HIV medications when ... would open the door to a functional cure for all ...
(Date:7/11/2014)... UK (PRWEB) July 11, 2014 Microbiology ... of the in-vitro diagnostics industry, which is expected to ... ten years. The sector owes its growth to the ... to people’s health worldwide and a major factor leading ... technologies, threat of bio-terrorism, and a broader availability of ...
(Date:7/11/2014)... 11, 2014 The report, “Specialty ... Applications & Geography - 2018,” defines and segments ... with an analysis and forecast of the volumes ... fibers (Para aramids, meta aramids, UHMW Polyethylene, carbon ... PPS fiber, PBI fiber, PBO fiber, and liquid ...
(Date:7/11/2014)... Datalogic brings a new and innovative ... wide. With their new Gryphon GD4400 and ... the devastating MRSA, which claimed 5,500 lives, becomes more ... 2D and the Gryphon GM4400-HC 2D readers can scan ... read barcodes off of troublesome LCD monitors, smartphones, and ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 ... least $50 billion in fuel costs now ... The current GHG standards are ... taken it upon themselves to install new ... , 1.    Idle reduction technologies , 2.    Efficient driveline ...
Breaking Medicine News(10 mins):Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3
... County residents will have the opportunity to witness a special, ... traditional lighting of the Saugatuck River Bridge at dusk. Those ... the door, will enjoy cuisine and drink from some of ... chance to participate in a silent auction that includes items ...
... VIEW, Calif., July 7 ... has closed its acquisition of the Managed Security Services ... VeriSign is the trusted provider of Internet infrastructure services ... strengthens its leadership position as a global, pure-play security ...
... , MORTON GROVE, Ill., July 7 Lifeway Foods, Inc. (Nasdaq: ... a provider of other natural and organic dairy products, invites you ... throws out the first pitch before the Chicago Cubs take on ... , At this official "Lifeway Day with the Cubs," the local ...
... July 7 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (OTC Bulletin Board: ... and supplier of pharmaceutical,products and medical nutrients addressing a ... has commenced the full implementation of the,new rural cooperative ... Since the beginning of April, Biostar has deployed ...
... Web reports by states and municipalities , TUESDAY, July ... the United States get mixed marks for their use of ... outbreak, a new study shows. , After the U.S. government ... state health departments posted some information about the H1N1 outbreak ...
... the director of Developmental Care and Follow-up at Texas Children,s ... Medicine , has been appointed chair of the American Academy ... assumed the role on July 1st and will oversee the ... succeed Ann Stark, M.D., FAAP, chief of Neonatology at Texas ...
Cached Medicine News:Health News:Al's Angels' 'Angels in July' Saugatuck River Bridge Lighting to Benefit Children in Need 2Health News:SecureWorks Closes Acquisition of VeriSign's Managed Security Services Business 2Health News:SecureWorks Closes Acquisition of VeriSign's Managed Security Services Business 3Health News:SecureWorks Closes Acquisition of VeriSign's Managed Security Services Business 4Health News:Giant Bugs Invade Wrigley Field 2Health News:Biostar Pharmaceuticals, Inc. Commences the Full Implementation of New Rural Cooperative Supply Network Plan 2Health News:Biostar Pharmaceuticals, Inc. Commences the Full Implementation of New Rural Cooperative Supply Network Plan 3Health News:Mixed Marks for Swine Flu Updates 2Health News:The American Academy of Pediatrics Names Lu-Ann Papile, M.D., FAAP, as Chair of the Fetus and Newborn Committee 2Health News:The American Academy of Pediatrics Names Lu-Ann Papile, M.D., FAAP, as Chair of the Fetus and Newborn Committee 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: